| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Bioscience Research Division, Korea Research Institute of Bioscience & Biotechnology, Yusung, Taejeon 305-333, Korea
| ABSTRACT |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
To analyze DNA content by flow cytometry, we trypsinized cells; fixed them in 70% ethanol; resuspended them in Dulbeccos PBS containing RNase A (50 µg/ml), 0.1% sodium citrate, and propidium iodide (50 µg/ml); and then analyzed the samples with a FACScan (Becton Dickinson, Mountain View, CA) and Lysys software. To visualize condensed chromatin, we stained ethanol-fixed cells with propidium iodide, placed them on glass slides, and examined the slides under the fluorescence microscope (Carl Zeiss, Germany).
Protein Analysis.
Cell lysates were prepared as reported previously (16)
.
Briefly, cells were lysed with RIPA buffer [50 mM Tris (pH
7.5), 5 mM NaCl, 1 µM EGTA, 1% Triton X-100,
50 µM NaF, 10 µM
Na3VO4, 1 µg/ml
aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin A, 0.1
mM phenylmethylsulfonyl fluoride, and 1 mM
DTT], and the lysates were clarified by centrifugation (1200 rpm for
10 min at 4°C). To measure histone H1 kinase activity, we incubated
cell lysate (150 µg) for 12 h at 4°C with anti-cdc2 antibody
(sc-34; Santa Cruz Biotechnology, Santa Cruz, CA) and protein A-agarose
(Boehringer Mannheim Inc., Indianapolis, IN). The immunoprecipitates
were washed three times with RIPA buffer and twice with kinase buffer
[50 mM HEPES (pH 7.4), 10 mM
MgCl2, 2 mM DTT]. The
immunoprecipitates in the kinase buffer were mixed with 25 µl of
kinase buffer containing 20 µM ATP, 5 µCi of
[
-32P]ATP (3000 mCi/mmol; Amersham Corp.,
Buckinghamshire, United Kingdom), and 1.5 µg of histone H1
(Boehringer Mannheim). After 30 min at 30°C, the reactions were
terminated with SDS sample buffer, and the reaction products were
analyzed by SDS-PAGE and autoradiography.
Rabbit antibody against cyclin B1 (sc-752; Santa Cruz Biotechnology), mouse antibodies against cdc2 (sc-54; Santa Cruz Biotechnology) or p53 (sc-126; Santa Cruz Biotechnology), and goat antibody against actin (sc-1616; Santa Cruz Biotechnology) were used for immunoblot assay. Immunoblotting was performed with ECL Western blotting detection reagents (Amersham).
Northern Blot Analysis.
Total cellular RNA was isolated with the use of Trizol solution (Life
Technologies). RNA (15 µg) was analyzed by electrophoresis in 1%
agarose-formaldehyde gels and transferred to nitrocellulose filters.
Hybridizations were performed with the following
32P-labeled DNA probes: (a) the 1.2-kb
EcoRI/BamHI cdc2 insert fragment containing the
complete open reading frame of cdc2; (b) the 1.1-kb
KpnI/XbaI cyclin B1 insert in pRC/CMV plasmid;
(c) the 375-base fragment specific for the 3'
untranslated region of
was generated by PCR using EST W79136 as
template and the primers 5'-ACAGGGGAACTTTATTGAGAGG-3' and
5'-AAGGGCTCCGTGGAGAGG-G-3' (17)
. Hybridization conditions
and washing procedures were optimized according to the manufacturers
instructions (ExpressHyb; Clontech Inc., Palo Alto, CA).
| Results |
|---|
|
|
|---|
E1; Ref.
15
), mitosis occurred 812 h after release from the
G1-S block, as indicated by flow cytometric
analysis (Fig. 1A)
|
Transcriptions of the cdc2 and cyclin B1 genes
have been shown to be regulated in a cell cycle-dependent manner,
beginning at G1-S and reaching maximum levels at
G2-M (12
, 13)
. In cells infected
with a control virus, cdc2 and cyclin B1 mRNA peaked at 810 h (Fig. 2A)
. However, in cells infected with Ad-p53, cell
cycle-dependent increases in cdc2 and cyclin B1 mRNA levels were
abolished (Fig. 2A)
.
|
gene, which is a new member of the 14-3-3 gene family,
is induced in a p53-dependent manner after DNA damage and that its
overexpression leads to arrest at G2-M
(17)
. We examined 14-3-3
transcription after
release from the G1-S arrest (Fig. 2B)
remained at the
basal level during cell cycle progression in cells infected with a
control virus but was induced in cells infected with a virus that
encodes p53 (Fig. 2B)
Activation of cdc2 Kinase Overrides p53-mediated G2-M
Arrest.
To verify the role of the cdc2-cyclin B1 complex in p53-mediated
G2-M arrest, we examined whether constitutive
activation of cyclin B1-associated cdc2 kinase overrides p53-mediated
cell cycle arrest at the G2 checkpoint. To
achieve constitutive activation of cdc2 kinase, we used recombinant
adenoviruses that encode cyclin B1 or the dominant mutant form of cdc2,
cdc2AF, in which Thr-14 and Tyr-15 are changed to alanine and
phenylalanine, respectively (14)
. The cyclin B1and cdc2AF genes are under the control of a
tetracycline-repressible promoter; expression from this promoter
requires that cells are co-infected with a recombinant adenovirus that
encodes the tTA transactivator (18)
. These synchronized
cells were infected with adenoviruses that encode tTA and both cyclin
B1 and cdc2AF. Expression of both cdc2AF and cyclin B1 resulted in a
constitutive activation of the cdc2 kinase regardless of positions in
the cell cycle after release (Fig. 3C)
, whereas expression of either cdc2AF or cyclin B1 did not
significantly increase the cdc2 kinase activity (data not shown).
Whereas cells expressing p53 had no detectable cdc2 kinase activity,
cells expressing p53 together with cdc2AF and cyclin B1 showed a
constitutive activation of cdc2 kinase regardless of p53 expression
(Fig. 3C)
. Cells expressing tTA alone or tTA plus both cdc2
and cyclin B1 behaved identically to control cells infected with
Ad-
E1 in cell cycle progression and timing on mitosis entry (Fig. 3, A and B)
. Whereas cells expressing p53 were
arrested at G2-M for at least 24 h after
release, cells expressing p53 and both cdc2AF and cyclin B1 did not
arrest at G2-M, entering the next
G1 at 812 h, and chromosome condensation
occurred normally, as with control cells (Fig. 3, A and B)
. However, the cells were arrested at the next
G1, which is another arrest point mediated by p53
expression (Fig. 3A)
. These results suggest that
constitutive activation of cdc2 kinase permits cell to progress through
G2-M arrest, but not G1
arrest, in the presence of p53.
|
| Discussion |
|---|
|
|
|---|
In the human colorectal cancer cell line, HCT116, expression of the
14-3-3
gene is induced in a p53-dependent manner after
DNA damage, and its overexpression leads to arrest at
G2-M (17)
. The 14-3-3
protein has
been proposed to induce G2-M arrest by binding to
the nonfunctional phosphorylated form of cdc25C phosphatase, which in
turn prevents activation of cdc2 (20)
. Transcription of
14-3-3
was induced in EJ cells infected with Ad-p53
during cell cycle progression (Fig. 2B)
. If p53 inhibits
cdc2 kinase through accumulation of 14-3-3
, the phosphorylated
fractions of cdc2 should increase in cells infected with an adenovirus
that encodes p53. However, as shown in Fig. 1C
,
phosphorylated forms of cdc2 were decreased and finally became
undetectable after release from G1-S arrest in
the presence of p53. These results suggest that 14-3-3
does not
affect cdc2 phosphorylation in EJ cells infected with Ad-p53. Recently,
Winters et al. (21)
reported that inactivation
of cdc2 kinase after DNA damage results from nuclear translocation
rather than inhibitory phosphorylation of cdc2 in p53-expressing H1299
cells. Therefore, it is unlikely that p53 inhibits cdc2 kinase through
the inhibitory phosphorylation of cdc2. Instead, p53 inhibits cdc2
kinase activity through repression of cyclin B1 and cdc2. We previously
reported that p53 represses cdc2 and cyclin B1 promoters
(16)
; therefore, it is likely that p53-mediated repression
of cdc2 and cyclin B1 mRNA levels results from inactivation of the
promoters. The NF-Y transcription factor, which binds to the CCAAT
sequences on these promoters, seems to mediate repression by p53
(16)
. Recently, it was suggested that NF-Y is involved in
cell cycle-dependent activation of cyclin B1 promoter
(22)
. Taking observations of this and other groups
together, we propose that p53 inactivates the
G2-specific cyclin-cdk complex, cyclin B1-cdc2,
through at least three different routes: transcription repression of
cdc2 and cyclin B1 (Fig. 2A
and Ref.
16
); transcription activation of 14-3-3
(17)
; and nuclear localization of cyclin B1-cdc2
(21)
.
Recently, it was reported that transient overexpression of cyclin B1
alone leads to decrease in G2-M population in
growth-arrested cells by a temperature-sensitive p53 gene
(23)
. However, expression of either cdc2AF or cyclin B1 at
normal levels, using a tetracycline-repressible promoter in the HeLa S3
cell line, has only minor effects on cell cycle progression at
G2-M (14)
. Although expression of
cyclin B1 alone did not affect to the G2-M arrest
that follows DNA damage, expression of both cdc2 and cyclin B1 reduced
the damage-induced G2 delay (14)
. In
this study, we expressed cyclin B1 and/or cdc2AF by use of a
tetracycline-repressible promoter in the synchronized p53-deficient EJ
cells. Expression of either cdc2AF or cyclin B1 had no significant
effects in the p53-mediated G2-M arrest (data not
shown). By contrast, when both cdc2AF and cyclin B1 were expressed,
cdc2 kinase was activated regardless of cell cycle position. Under this
condition, cells pass through G2-M in the
presence of p53. These results suggest that inactivation of cyclin
B1-cdc2 is an essential step of p53-mediated G2-M
arrest. Previous reports have indicated that cyclin B1 destruction is
required for exit from mitosis (14
, 24)
. However, the
cells expressing cdc2AF and cyclin B1 normally exited from mitosis and
entered the next G1 phase (Fig. 3)
, presumably
because of the relatively low expression of cyclin B1 in those cells.
In summary, our study clearly demonstrates that inhibition of cdc2 kinase through p53-mediated cdc2 and cyclin B1 repression is essential for G2-M arrest.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
1 Supported in part by the Korean Ministry of
Science and Technology, the Korean National Cancer Control Program, and
the Korea Science & Engineering Foundation (all to S. D. Y.). ![]()
2 To whom requests for reprints should be
addressed, at Bioscience Research Division, Korea Research Institute of
Bioscience & Biotechnology, Yusung, Taejeon, 305-333, Korea. Phone:
82-42-860-4128; Fax: 82-42-860-4606; E-mail: dyshin{at}mail.kribb.re.kr ![]()
Received 10/ 4/99. Accepted 12/10/99.
| REFERENCES |
|---|
|
|
|---|
is a p53-regulated inhibitor of G2/M progression. Mol. Cell, 1: 3-11, 1997.[Medline]
This article has been cited by other articles:
![]() |
Y. Song, C. Zhao, L. Dong, M. Fu, L. Xue, Z. Huang, T. Tong, Z. Zhou, A. Chen, Z. Yang, et al. Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis Carcinogenesis, February 1, 2008; 29(2): 307 - 315. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Ghosh, R. Steele, and R. B. Ray Knockdown of MBP-1 in Human Prostate Cancer Cells Delays Cell Cycle Progression J. Biol. Chem., August 18, 2006; 281(33): 23652 - 23657. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Roberson, S. J. Kussick, E. Vallieres, S.-Y. J. Chen, and D. Y. Wu Escape from Therapy-Induced Accelerated Cellular Senescence in p53-Null Lung Cancer Cells and in Human Lung Cancers Cancer Res., April 1, 2005; 65(7): 2795 - 2803. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. W. Elmore, X. Di, C. Dumur, S. E. Holt, and D. A. Gewirtz Evasion of a Single-Step, Chemotherapy-Induced Senescence in Breast Cancer Cells: Implications for Treatment Response Clin. Cancer Res., April 1, 2005; 11(7): 2637 - 2643. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Shats, M. Milyavsky, X. Tang, P. Stambolsky, N. Erez, R. Brosh, I. Kogan, I. Braunstein, M. Tzukerman, D. Ginsberg, et al. p53-dependent Down-regulation of Telomerase Is Mediated by p21waf1 J. Biol. Chem., December 3, 2004; 279(49): 50976 - 50985. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-R. Lin, N. S. Y. Ting, J. Qin, and W.-H. Lee M Phase-specific Phosphorylation of BRCA2 by Polo-like Kinase 1 Correlates with the Dissociation of the BRCA2-P/CAF Complex J. Biol. Chem., September 19, 2003; 278(38): 35979 - 35987. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yun, H.-D. Chae, T.-S. Choi, E.-H. Kim, Y.-J. Bang, J. Chung, K.-S. Choi, R. Mantovani, and D. Y. Shin Cdk2-dependent Phosphorylation of the NF-Y Transcription Factor and Its Involvement in the p53-p21 Signaling Pathway J. Biol. Chem., September 19, 2003; 278(38): 36966 - 36972. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Lohr, C. Moritz, A. Contente, and M. Dobbelstein p21/CDKN1A Mediates Negative Regulation of Transcription by p53 J. Biol. Chem., August 29, 2003; 278(35): 32507 - 32516. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Polager and D. Ginsberg E2F Mediates Sustained G2 Arrest and Down-regulation of Stathmin and AIM-1 Expression in Response to Genotoxic Stress J. Biol. Chem., January 10, 2003; 278(3): 1443 - 1449. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Hassan, K. K. Ang, A. K. El-Naggar, M. D. Story, J. I. Lee, D. Liu, W. K. Hong, and L. Mao Cyclin B1 Overexpression and Resistance to Radiotherapy in Head and Neck Squamous Cell Carcinoma Cancer Res., November 15, 2002; 62(22): 6414 - 6417. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Farhana, M. Dawson, A. K. Rishi, Y. Zhang, E. Van Buren, C. Trivedi, U. Reichert, G. Fang, M. W. Kirschner, and J. A. Fontana Cyclin B and E2F-1 Expression in Prostate Carcinoma Cells Treated with the Novel Retinoid CD437 Are Regulated by the Ubiquitin-mediated Pathway Cancer Res., July 1, 2002; 62(13): 3842 - 3849. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, J. Li, R. N. Booher, A. Kraker, T. Lawrence, W. R. Leopold, and Y. Sun Radiosensitization of p53 Mutant Cells by PD0166285, a Novel G2 Checkpoint Abrogator Cancer Res., November 1, 2001; 61(22): 8211 - 8217. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-Y. Yin, L. Grove, N. S. Datta, K. Katula, M. W. Long, and E. V. Prochownik Inverse Regulation of Cyclin B1 by c-Myc and p53 and Induction of Tetraploidy by Cyclin B1 Overexpression Cancer Res., September 1, 2001; 61(17): 6487 - 6493. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-C. Soria, S. J. Jang, F. R. Khuri, K. Hassan, D. Liu, W. K. Hong, and L. Mao Overexpression of Cyclin B1 in Early-Stage Non-Small Cell Lung Cancer and Its Clinical Implication Cancer Res., August 1, 2000; 60(15): 4000 - 4004. [Abstract] [Full Text] |
||||
![]() |
P. M. Flatt, L. J. Tang, C. D. Scatena, S. T. Szak, and J. A. Pietenpol p53 Regulation of G2 Checkpoint Is Retinoblastoma Protein Dependent Mol. Cell. Biol., June 15, 2000; 20(12): 4210 - 4223. [Abstract] [Full Text] |
||||
![]() |
I. Manni, G. Mazzaro, A. Gurtner, R. Mantovani, U. Haugwitz, K. Krause, K. Engeland, A. Sacchi, S. Soddu, and G. Piaggio NF-Y Mediates the Transcriptional Inhibition of the cyclin B1, cyclin B2, and cdc25C Promoters upon Induced G2 Arrest J. Biol. Chem., February 16, 2001; 276(8): 5570 - 5576. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Casalini, L. Botta, and S. Menard Role of p53 in HER2-induced Proliferation or Apoptosis J. Biol. Chem., April 6, 2001; 276(15): 12449 - 12453. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |